|Last Price$12.56||Day Change (%)0.00%|
|Open Price$12.56||Day Change ($)0.00|
|Day Range12.56–12.56||52-Week Range12.19–12.80|
As of Fri 05/26/2017 | USD
MetaStat Elevates Jerome B. Zeldis, M.D., Ph.D. to Chairman of the Board and Appoints Douglas A. Hamilton, MetaStat’s President and CEO to its Board of Directors
Despite the high 39% premium to Hospira's stock price, we believe the acquisition price is justified based on Pfizer's ability to unlock more value with its global reach.
Welcome to Hospira's First Quarter 2014 Conference Call. All lines have been placed on listen-only mode to prevent any background noise. Following the speakers' remarks, there will be a question-and-answer period.
Global Neutropenia Treatment Market - Analysis, Technologies & Forecasts to 2021 - Paradigm Shift in Management of Febrile Neutropenia - Research and Markets
Four candidates stood out from their growth counterparts.